Efficacy (%) | Value | Lower | Upper | Source |
---|---|---|---|---|
Clinical cure (1st) of CTZ/TAZ | 60.7 | 61.0 | 72.0 | |
Clinical cure (1st) of MEPM | 57.1 | 49.0 | 75.0 | |
Mortality (1st) of CTZ/TAZ | 20.1 | 20.0 | 31.0 | |
Mortality (1st) of MEPM | 25.5 | 12.0 | 28.0 | |
Clinical cure (2nd) of CTZ/TAZ | 56.8 | 57.1 | 69.2 | |
Clinical cure (2nd) of MEPM | 52.8 | 43.9 | 72.5 | |
Mortality (2nd) of CTZ/TAZ | 24.1 | 24.0 | 37.2 | |
Mortality (2nd) of MEPM | 30.6 | 14.4 | 33.6 | |
Administration duration (Day) | ||||
1st-line treatment of CTZ/TAZ | 8 | 7.64 | 8.36 | [18] |
1st-line treatment of MEPM | 8.23 | 7.86 | 8.6 | |
2nd-line treatment of CTZ/TAZ | 7 | 4 | 10 | [10] |
2nd-line treatment of MEPM | 7 | 4 | 10 | |
ICU LOS (day) | ||||
1st-line treatment of CTZ/TAZ | 28.0 | 16 | 28 | [21] |
1st-line treatment of MEPM | 24.0 | 15 | 28 | |
2nd-line treatment of CTZ/TAZ | 21.0 | 20 | 23 | |
2nd-line treatment of MEPM | 21.0 | 20 | 23 | |
Mechanical ventilation duration (Day) | ||||
1st-line treatment of CTZ/TAZ | 12 | 5 | 28 | [21] |
1st-line treatment of MEPM | 13 | 6 | 28 | |
2nd-line treatment of CTZ/TAZ | 12 | 5 | 28 | |
2nd-line treatment of MEPM | 12 | 5 | 28 | |
Adverse Event rate (%) | ||||
Septic shock of CTZ/TAZ | 3.6 | [14] | ||
Multiorgan failure of CTZ/TAZ | 3.9 | |||
Acute cardiac failure of CTZ/TAZ | 2.5 | |||
Septic shock of MEPM | 4.7 | |||
Multiorgan failure of MEPM | 2.8 | |||
Acute cardiac failure of MEPM | 2.2 | |||
Acute renal failure of AMK | 6.0 | 0.0 | 27.6 | [23] |